Endothelin receptor blockade and nitric oxide bioactivity.
Barton
M
M
Glodny
B
B
D000109:Acetylcholine / Q000494:pharmacology*; D000077300:Bosentan; D001026:Coronary Artery Bypass; D003327:Coronary Disease / Q000378:metabolism / Q000503:physiopathology* / Q000601:surgery; D065128:Endothelin Receptor Antagonists; D004730:Endothelium, Vascular / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology*; D005260:Female; D006801:Humans; D066298:In Vitro Techniques; D008297:Male; D008323:Mammary Arteries / Q000378:metabolism; D009569:Nitric Oxide / Q000378:metabolism; D009842:Oligopeptides / Q000494:pharmacology; D010456:Peptides, Cyclic / Q000494:pharmacology; D010880:Piperidines / Q000494:pharmacology; D017466:Receptors, Endothelin / Q000378:metabolism; D013449:Sulfonamides / Q000494:pharmacology; D014664:Vasodilation; D014665:Vasodilator Agents / Q000494:pharmacology
D065128:Endothelin Receptor Antagonists; D009842:Oligopeptides; D010456:Peptides, Cyclic; D010880:Piperidines; D017466:Receptors, Endothelin; D013449:Sulfonamides; D014665:Vasodilator Agents; D009569:Nitric Oxide; C086539:BQ 788; D000109:Acetylcholine; D000077300:Bosentan; C072247:cyclo(Trp-Asp-Pro-Val-Leu)